Isocoumarin-pyrazole hybrids selectively inhibit hCA IX and XII isoforms, offering a novel scaffold for designing selective anticancer agents without off-target effects.
Isocoumarin-pyrazole hybrids selectively inhibit hCA IX and XII, offering a novel chemical scaffold for the design of selective anticancer agents.
Absolute Event Rate: 0% vs 0%
This study shows that isocoumarin - pyrazole hybrids achieve selective inhibition of hCA IX and XII without affecting off-target isoforms. The results expand the chemical space of non-classical CA inhibitors and offer insights for the rational design of selective anticancer agents. Future work will focus on optimizing potency and evaluating efficacy in cellular tumor models.
Onyilmaz et al. (Sat,) reported a other. Isocoumarin-pyrazole hybrids selectively inhibit hCA IX and XII isoforms, offering a novel scaffold for designing selective anticancer agents without off-target effects.